Evidence map›Paper›PMID 31828567›Full record

ArticleGlycoconjugate journal2020

Interactions between Sclerostin and Glycosaminoglycans.

Fuming Zhang, Jing Zhao, Xinyue Liu, Robert J Linhardt

Abstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Sclerostin: From Molecule to Clinical Biomarker.International journal of molecular sciences · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fuming ZhangDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA. zhangf2@rpi.edu.ORCID 0000-0003-2803-3704
Jing ZhaoDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Xinyue LiuDepartment of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Robert J LinhardtDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA. linhar@rpi.edu.
Rensselaer Polytechnic Institute · US

Funding

NIH HHS AG062344NIH HHS CA231074NIH HHS DK111958
6 · The paper itself

Abstract

Sclerostin (SOST) is a glycoprotein having many important functions in the regulation of bone formation as a key negative regulator of Wnt signaling in bone. Surface plasmon resonance (SPR), which allows for a direct quantitative analysis of the label-free molecular interactions in real-time, has been widely used for the biophysical characterization of glycosaminoglycan (GAG)-protein interactions. In the present study, we report kinetics, structural analysis and the effects of physiological conditions (e.g., salt concentrations, Ca

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCalciumChondroitinHeparinHumansMiceOsmolar ConcentrationProtein BindingRecombinant ProteinsZincAdaptor Proteins, Signal TransducingCalciumChondroitinHeparinRecombinant ProteinsSOST protein, humanSost protein, mouseZincGlycosaminoglycansHeparinInteractionSclerostinSurface plasmon resonance

Identifiers

PMID31828567
OpenAlexW2995538029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.